These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 19165437

  • 1. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 2. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Jan; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 4. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 5. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Feb; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 6. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 7. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

  • 8. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 9. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G.
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [Abstract] [Full Text] [Related]

  • 10. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Mar; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 12. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 13. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Feb; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 14. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U, Stöckl G, Ebelt H, Nuding S, Höpfner F, Werdan K, ADDITIONS Study Investigators.
    Exp Gerontol; 2014 Nov; 59():34-41. PubMed ID: 25193811
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Nov; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 16. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 17. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A, Tardif JC.
    Adv Cardiol; 2006 Feb; 43():65-78. PubMed ID: 16936473
    [Abstract] [Full Text] [Related]

  • 18. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct 27; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 20. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr 27; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.